Loading...
OTCM
SSMXY
Market cap5.66bUSD
Jul 09, Last price  
9.33USD
1D
-4.31%
1Q
7.36%
Jan 2017
-51.74%
Name

Sysmex Corp

Chart & Performance

D1W1MN
OTCM:SSMXY chart
P/E
24.38
P/S
1.73
EPS
62.12
Div Yield, %
2.37%
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
11.69%
Revenues
530.16b
+4.23%
101,041,000,000110,724,000,000111,842,000,000116,174,000,000124,694,000,000134,743,000,000145,577,000,000184,538,000,000221,376,000,000252,622,000,000249,899,000,000281,935,000,000293,506,000,000301,980,000,000305,073,000,000363,780,000,000410,502,000,000461,510,000,000508,643,000,000530,160,285,000
Net income
37.59b
-29.95%
9,008,000,0009,131,000,0008,013,000,0009,764,000,00011,411,000,00012,007,000,00014,165,000,00020,573,000,00026,638,000,00039,278,000,00040,635,000,00039,221,000,00041,224,000,00034,882,000,00031,904,000,00044,092,000,00045,784,000,00049,639,000,00053,669,000,00037,594,275,000
CFO
78.30b
-11.27%
10,085,000,00011,634,000,00013,193,000,00021,229,000,00018,135,000,00017,058,000,00025,806,000,00036,563,000,00038,640,000,00041,794,000,00032,832,000,00052,240,000,00044,743,000,00053,182,000,00056,873,000,00058,739,000,00068,835,000,00063,905,000,00088,246,000,00078,301,614,000
Dividend
Sep 30, 20250.10435 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Kobe, Japan, Sysmex Corporation is a global leader in the creation, production, and distribution of sophisticated diagnostic instruments, chemical reagents, and related software. Their extensive product portfolio addresses a wide array of laboratory needs. Within hematology, Sysmex provides advanced three-part and five-part white blood cell differentiation instruments, alongside efficient transport systems designed for high-throughput laboratory environments. Their offerings further encompass automated analyzers for both urine particles and blood coagulation. The company also specializes in automated immunochemistry systems, capable of performing intricate assays on minute sample volumes, complemented by reagents for detecting infectious diseases and tumor markers. Additionally, Sysmex manufactures essential flow cytometers utilized in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core diagnostic tools, Sysmex offers specialized systems for detecting cancer lymph node metastasis and provides comprehensive laboratory assay services. The company's operations extend into developing and commercializing software for diagnostic information systems, and delivering a range of services including facility management, administrative support, employee welfare, and genetic analysis. They are deeply involved in the conception, operation, and maintenance of IT solutions, platforms, and applications tailored for digital medicine. Sysmex also actively participates in the entire lifecycle of medical robots, from marketing and development to design, manufacturing, sales, and post-sales support. Furthermore, the company manages the distribution and after-sales support for medical devices and reagents used across biotechnology, medical technology, and molecular cell analysis. Sysmex is committed to research, development, manufacturing, and commercialization of regenerative medicine products and biodevices, while also developing, maintaining, and selling general computer software and offering blood DNA testing services. Sysmex serves a diverse international client base, including national and public hospitals, private healthcare facilities, universities, research institutions, and various other medical organizations. Their global reach is substantial, with product exports to approximately 190 countries. Founded in 1968, the company initially operated as TOA Medical Electronics Co., Ltd., adopting the name Sysmex Corporation in October 1998.
IPO date
Nov 15, 1995
Employees
9,500
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT